A complementary drug to combat Alzheimer’s disease could target a specific part of the nerve cell protein tau. This is the ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...

A research team has discovered that the two key pathological hallmarks of Alzheimer's -- tau protein and beta-amyloid -- affect brain circuits in distinct yet synergistic ways, particularly those ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test can detect small amounts of the clumping-prone tau protein and its misfolded pathological forms ...

Researchers say CSF biomarker test correlates with the severity of cognitive decline, independent of other factors, including brain amyloid deposition.

PITTSBURGH (KDKA) — A breakthrough in the fight against Alzheimer's was made by researchers at the University of Pittsburgh, where a test was created to detect the disease in the brain earlier.

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...

A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau. This is the ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the ...

Researchers from the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) have found that tau protein and beta-amyloid – two pathological hallmarks of Alzheimer’s disease – ...

Scientists develop groundbreaking dual-action drug RI-AG03 that targets toxic tau proteins in Alzheimer's disease, showing ...